Posaconazole indications and usage

Posaconazole
NOXAFIL® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Indications And Usage

Prophylaxis of Invasive Aspergillus and Candida Infections

Noxafil® delayed-release tablets and oral suspension are indicated for:

• Prophylaxis of invasive Aspergillus

• Prophylaxis of Candida infections

in patients with

• 13 years of age and older
• High risk of developing these infections
• Severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.

Treatment of Oropharyngeal Candidiasis Including Oropharyngeal Candidiasis Refractory to Itraconazole and/or Fluconazole

Noxafil oral suspension is indicated for the treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole.

References

Adapted from the FDA Package Insert.